Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.2%

10 terminated/withdrawn out of 55 trials

Success Rate

70.6%

-15.9% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

58%

14 of 24 completed trials have results

Key Signals

8 recruiting14 with results5 withdrawn

Enrollment Performance

Analytics

Phase 1
25(46.3%)
Phase 2
21(38.9%)
N/A
6(11.1%)
Phase 3
1(1.9%)
Early Phase 1
1(1.9%)
54Total
Phase 1(25)
Phase 2(21)
N/A(6)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (55)

Showing 20 of 55 trials
NCT05812274Not ApplicableTerminated

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Role: collaborator

NCT06015659Phase 2Active Not Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Role: collaborator

NCT04434040Phase 2Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Role: collaborator

NCT03803553Phase 3Recruiting

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Role: collaborator

NCT05886764Not ApplicableActive Not Recruiting

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Role: collaborator

NCT04262154Phase 2Active Not Recruiting

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Role: collaborator

NCT05918640Phase 1Recruiting

Lurbinectedin in FET-Fused Tumors

Role: collaborator

NCT03568422Phase 1Active Not Recruiting

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Role: collaborator

NCT06070870Not ApplicableRecruiting

Health Education Approach to Lung Screening

Role: collaborator

NCT04469556Phase 2Completed

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Role: collaborator

NCT05995821Recruiting

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Role: collaborator

NCT06208657Phase 1Recruiting

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Role: collaborator

NCT04995003Phase 1Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Role: collaborator

NCT03875287Phase 1Active Not Recruiting

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Role: collaborator

NCT03602157Phase 1Active Not Recruiting

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Role: collaborator

NCT05714644Not ApplicableCompleted

Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening

Role: collaborator

NCT05013216Phase 1Recruiting

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Role: collaborator

NCT03762590Not ApplicableActive Not Recruiting

GENetic Education Risk Assessment and TEsting Study

Role: collaborator

NCT03563248Phase 2Active Not Recruiting

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Role: collaborator

NCT03220477Phase 1Active Not Recruiting

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Role: collaborator